Two studies, one positive and one negative, give proponents and skeptics more data to parse in debating whether genomically guided treatment has broad value in lung cancer.
The promising response rates seen in the SUMMIT trial may provide further reason to broadly test all advanced cervical cancer patients for precision medicine biomarkers.
Based on the expression of S100A2 and S100A4 proteins, researchers predicted which patients were likely to experience poor outcomes and disease recurrence post-surgery.
The new mutation may allow public health programs to refine inherited cancer risk screening for individuals in Brazil who also have the TP53-R337H mutation.
Despite recognition among drugmakers, researchers, and regulators of the need to diversify precision oncology trials, few Black and Hispanic patients are included in studies.
Researchers reported a correlation between ctDNA clearance and progression-free survival in EGFR-positive, MET-amplified patients treated with Tagrisso and savolitinib.
As MacroGenics advances flotetuzumab through AML studies, it is working with researchers to refine the predictive ability of the gene expression signature.
